Skip to main content Back to Top


Norepinephrine Bitartrate Injection

Products Affected - Description

    • Levophed injection, Pfizer, 1 mg/mL, 4 mL ampule, 10 count, NDC 00409-1143-04

Reason for the Shortage

    • Baxter has norepinephrine injection available.
    • Mylan Institutional refuses to provide product availability.
    • Pfizer has Levophed on shortage due to manufacturing delays.
    • Teva had norepinephrine injection on allocation due to increased demand.

Available Products

    • Levophed injection, Pfizer, 1 mg/mL, 4 mL vial, 10 count, NDC 00409-3375-04
    • Norepinephrine injection, Baxter, 1 mg/mL, 4 mL ampule, 10 count, NDC 36000-0162-10
    • Norepinephrine injection, Teva, 1 mg/mL, 4 mL vial, 10 count, NDC 00703-1153-03

Estimated Resupply Dates

    • Pfizer has Levophed 1 mg/mL 4 mL ampules on back order and the company estimates a release date of March 2020. The 4 mL vials are available in limited supply.


Updated October 4, 2019 by Anthony Trovato, PharmD, BCPS. Created February 22, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins